Member since: 2020
User friendly organ on a chip system.
Application Area: Benchtop lab on a chip system
"User-friendly microfluidic system for 3D multicellular culture. Easy to clean and maintain. Suitable for development of disease relevant cell models."
After years of costly research and development, many drug discovery programs fail because 2D cell culture and animal models do not adequately predict human responses. To mitigate the risk of late-stage failures in the clinic, researchers are increasingly adopting OOC technology to predict drug efficacy, toxicity, and pharmacokinetic profiles early in programs. Insights generated using OOC are being used to complement data derived using traditional methods, confirm discoveries, overcome inter-species differences, and bridge knowledge gaps. However, in certain scenarios, such as the development of new human-specific modalities, OOC offers a novel opportunity to validate a target hypothesis, test safety and efficacy where animal models may be altogether unsuitable due to differences in gene sequence or immunological response.
How does the PhysioMimix OOC MPS system complement existing approaches?
PhysioMimix™ OOC Systems facilitate the formation of 3D microtissues, or miniature organs, that behave and respond to drugs in the same way as a human by culturing multiple human cell types in a physiologically relevant environment. They maintain the phenotype and biological activity of cultures over weeks by mimicking blood flow around the human body, exposing cells to vital biomechanical stimuli, oxygen and nutrients.
The PhysioMimix™ OOC Single-Organ System enables detailed individual organ function and disease state modelling studies, using the MPS-LC12 consumable plate to generate in vitro 3D liver microtissues that mimic the human liver microarchitecture, or the MPS-T12 consumable plate to develop barrier models (such as gut or lung) on Transwell® inserts.
Providing additional functionality, the Multi-Organ System enables scientists to interconnect our liver-on-a-chip model with other organs, such as gut, lung or kidney. By mimicking how organs interact and communicate as part of a complex system, researchers benefit from a deeper human-specific mechanistic understanding of disease states and drug behaviour such as the ability to analyse target organ versus off-target effects, pharmacokinetics, bioavailability and biodistribution. This capability is facilitated by the MPS-TL6 consumable plate whose novel microfluidics enable recirculation of media from one culture compartment to the other to permit inter-organ crosstalk. When combined with PBPK mathematical modelling, in vitro data may be extrapolated to in vivo clinical predictions.
Through its ability to recreate human physiology in the lab, the PhysioMimix™ OOC can predict human responses to new therapeutic drug candidates. By supplementing data generated from entrenched 2D cell culture and animal studies, this system supports confident decision making across many drug discovery stages from target discovery right through to development.
Its applications include:
System features and benefits
Despite the complex biology that they recreate, PhysioMimix™ OOC Systems are simple to install (< 1hr) and user-friendly to operate (< 1 min to program and start a run). To support users transitioning from 2D cell culture into 3D microtissues, a familiar open-well plate-based format has been incorporated into the design of consumables to ease adoption.
First launched in 2018, this patented, proven technology offers the following features and benefits: